METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Clinical trials for METASTATIC CLEAR CELL RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CLEAR CELL RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Mushroom compound targets kidney cancer in dialysis patients
Disease control Recruiting nowThis early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Oncorena AB • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Kidney cancer patients may get a drug holiday thanks to new scan technique
Disease control Recruiting nowThis study tests whether people with advanced kidney cancer can safely pause their medication after one year of treatment. Doctors will use a special PET scan that targets CD70 to decide who qualifies for a treatment break. The goal is to see if patients can stop drugs without th…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New Immune-Boosting drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Gut bacteria boost may resensitize kidney tumors to immunotherapy
Disease control Recruiting nowThis study tests whether altering gut bacteria can restore the effectiveness of immunotherapy in people with advanced kidney cancer. About 33 adults will receive a bowel cleanse, a live bacterial supplement, and then a combination of immunotherapy drugs. The goal is to see if thi…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a common food fiber boost immunotherapy in kidney cancer?
Disease control Recruiting nowThis study tests whether adding inulin gel, a fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with metastatic or locally advanced clear cell or sarcomatoid kidney cancer will take part. Research…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New combo therapy aims to slow advanced kidney cancer
Disease control Recruiting nowThis study tests whether adding the experimental drug casdatifan to the standard drug cabozantinib can slow cancer growth better than cabozantinib alone in people with advanced clear cell kidney cancer. About 720 adults whose cancer worsened after prior immunotherapy will receive…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a gut bacteria boost cancer immunotherapy? new trial launches
Disease control Recruiting nowThis early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the s…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug cocktail aims to fight kidney cancer when immunotherapy fails
Disease control Recruiting nowThis study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with …
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gut bacteria boosts immunotherapy in kidney cancer fight?
Disease control Recruiting nowThis phase 3 trial tests whether adding a live biotherapy called MO-03 to standard immunotherapy can help control advanced or metastatic clear cell renal cell carcinoma. MO-03 is designed to improve gut health, which may make immunotherapy work better. About 718 participants will…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Modified virus boosts immunotherapy in kidney cancer trial
Disease control Recruiting nowThis phase 2 trial tests whether adding a lab-modified virus (VSV-IFNβ-NIS) to standard immunotherapy drugs (ipilimumab and nivolumab) can shrink tumors in people with advanced or metastatic clear cell kidney cancer. The virus is designed to kill cancer cells without harming norm…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Prostate cancer drug shows promise for kidney cancer in new trial
Disease control Recruiting nowThis study tests a radioactive drug, 177Lu-PSMA-617, in people with advanced kidney cancer that has spread and worsened despite standard treatments like immunotherapy and targeted therapy. The drug targets a protein called PSMA found on kidney cancer cells, delivering radiation d…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to keep kidney cancer in check without harsh treatment
Disease control Recruiting nowThis phase 2 trial tests whether the drug belzutifan can control metastatic clear cell renal cell carcinoma in people who are currently just being watched (active surveillance). Researchers will compare belzutifan to continued observation in 78 adults with slow-growing disease wh…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Gene test may guide kidney cancer therapy choice
Disease control Recruiting nowThis study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immuno…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for cancer patients who stopped responding to immunotherapy?
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—retifanlimab and ruxolitinib—can safely help people with advanced lung or kidney cancer whose disease has progressed after prior immunotherapy. About 40 participants will take ruxolitinib pills twice daily and receive …
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Triple attack on kidney cancer: immune booster, radiation, and immunotherapy
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (IMSA101) and targeted radiation to standard immunotherapy can help control metastatic kidney cancer that has started to grow again. About 15 adults with clear cell kidney cancer that has progressed in up to 5 spots will rec…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New study tests kidney cancer combo in patients over 70
Disease control Recruiting nowThis study is looking at how older patients (70 years and older) with advanced kidney cancer handle a combination of two drugs: cabozantinib (a daily pill) and nivolumab (an IV infusion). The goal is to see how doctors actually use these drugs in real life, including starting dos…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE4 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Should kidney cancer patients have surgery alongside immunotherapy? a major trial aims to find out
Disease control Recruiting nowThis phase III trial is testing whether adding surgery to remove the kidney (nephrectomy) to standard immunotherapy drugs helps people with kidney cancer that has spread live longer. About 364 participants will either receive immunotherapy alone or immunotherapy plus surgery. The…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New imaging agent aims to spot Hard-to-Find kidney cancer spread
Diagnosis Recruiting nowThis early study tests whether a new radioactive tracer called 111In-XYIMSR-01 can help detect clear cell kidney cancer that has spread to other parts of the body. Six adults with confirmed metastatic clear cell renal cell carcinoma will receive the tracer and then undergo a SPEC…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
Tiny study probes bone microenvironment in metastatic kidney cancer
Knowledge-focused Recruiting nowThis early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study uses PET scans to see how kidney cancer drug changes key protein
Knowledge-focused Recruiting nowThis early-phase study is looking at how the drug belzutifan affects a protein called CAIX in people with advanced clear cell kidney cancer. Researchers will use a special PET scan before and after four weeks of belzutifan treatment to measure changes in CAIX levels. The goal is …
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Tiny virus may hold key to kidney cancer treatment success
Knowledge-focused Recruiting nowThis pilot study is looking at whether levels of a common virus called TTV can help predict how well immunotherapy works in people with advanced kidney cancer. Researchers will measure TTV levels in 20 patients before and during their first immunotherapy treatment. The goal is to…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Sponsor: Regina Elena Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: METASTATIC CLEAR CELL RENAL CELL CARCINOMA
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC